Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype

British Journal of Clinical Pharmacology

Volumn 68, Issue 6, 2009, Pages 906-915

  Scholz, Ina ^a   Oberwittler, Heike ^a   Riedel, Klaus Dieter ^a   Burhenne, Jürgen ^a   Weiss, Johanna ^a   Haefeli, Walter E ^a   Mikus, Gerd ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Bioavailability; CYP2C19; Metabolism; Pharmacokinetics; Voriconazole

Indexed keywords

CYTOCHROME P450 2C19; DRUG METABOLITE; VORICONAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSIENT ENHANCED LIGHT PERCEPTION; URINALYSIS; VISUAL DISORDER;

ADMINISTRATION, ORAL; ADULT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FEMALE; GENOTYPE; GERMANY; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; PYRIMIDINES; TRIAZOLES; YOUNG ADULT;

EID: 70849109113     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03534.x     Document Type: Article

References (20)

1. Fachinformation VFEND. FachInfo. Fachinformationsverzeichnis. Deutschland 2008 Ausgabe 2008/6: BPI Service Gmbh.
2. Ghannoum MA, Kuhn DM. Voriconazole - better chances for patients with invasive mycoses. Eur J Med Res 2002 7 : 242 56.
3. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003 31 : 540 7.
4. Weiss J, ten Hoevel MM, Burhenne J, Walter-Sack I, Hoffmann MM, Rengelshausen J, Haefeli WE, Mikus G. CYP2C19 genotype is a major factor contributing to the highly variably pharmacokinetics of voriconazole. J Clin Pharmacol 2009 49 : 196 204.
5. Wood N, Tan K, Purkins L, Layton G, Hamlin J, Kleinermans D, Nichols D. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol 2003 56 (Suppl. 1 56 61. (Pubitemid 37491735)
6. Mikus G, Schöwel V, Drzewinska M, Rengelshausen J, Ding R, Riedel K-D, Burhenne J, Weiss J, Thomsen T, Haefeli W. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther 2006 80 : 126 35.
7. Purkins L, Wood N, Ghahramani P, Love ER, Eve MD, Fielding A. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br J Clin Pharmacol 2003 56 (Suppl. 1 37 44.
8. Rengelshausen J, Banfield M, Riedel K-D, Burhenne J, Weiss J, Thomsen T, Walter-Sack I, Haefeli WE, Mikus G. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther 2005 78 : 25 33.
9. Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima M. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 2004 75 : 587 8.
10. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry 1994 33 : 1743 52.
11. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994 269 : 15419 22.
12. de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994 46 : 594 8. (Pubitemid 24334747)
13. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997 7 : 59 64.
14. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006 79 : 103 13.
15. Xie HG, Huang SL, Xu ZH, Xiao ZS, He N, Zhou HH. Evidence for the effect of gender on activity of (S)-mephenytoin 4'-hydroxylase (CYP2C19) in a Chinese population. Pharmacogenetics 1997 7 : 115 9.
16. Purkins L, Wood N, Ghahramani P, Kleinermans D, Layton G, Nichols D. No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers. Br J Clin Pharmacol 2003 56 (Suppl. 1 30 6.
17. Briefing document for voriconazole (oral and intravenous formulations). FDA Antiviral Drugs Advisory Committee. Available at http://www.fda.gov/ohrms/ dockets/AC/01/briefing/3792b2-01-Pfizer.pdf (last accessed September 2009).
18. Pennick GJ, Clark M, Sutton DA, Rinaldi MG. Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother 2003 47 : 2348 50.
19. Obach RS, Zhang QY, Dunbar D, Kaminsky LS. Metabolic characterization of the major human small intestinal cytochrome p450s. Drug Metab Dispos 2001 29 : 347 52.
20. Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman AN, Smith DA, Walker DK, Wood N. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 2003 31 : 731 41.